BI-847325

Catalog No. A15762

BI-847325是一种生物利用型选择性MEK/Aurora双重激酶抑制剂，对于非洲爪蟾Aurora B，人Aurora A和Aurora C以及IC50分别为3 nM，25 nM，15 nM，25 nM和4 nM IC50人MEK1和MEK2。

Product Citations

Hilda Samimi, .et al. Alginate-based 3D cell culture technique to evaluate the half-maximal inhibitory concentration: an in vitro model of anticancer drug study for anaplastic thyroid carcinoma, Thyroid Res, 2021, Dec 3;14(1):27 PMID: 34861882
Hilda Samimi, .et al. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma, DARU J Pharm Sci, 2019, 1-7 PMID: 31077090

Technical details

Catalog Num	A15762
M. Wt	464.56
Formula	C29H28N4O2
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1207293-36-4
Synonyms	BI 847325, BI847325
SMILES	CCNC(C#CC1=CC=C2C(NC(/C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4)=O)=C1)=O

Biological Activity

Targets

Aurora B (Xenopus laevis)	MEK2	Aurora C (Human)	Aurora A (Human)	MEK1
3 nM	4 nM	15 nM	25 nM	25 nM

Solubility *

In vitro (25°C)	DMSO	Warmed: 19 mg/mL (40.89 mM)
	Water	Insoluble
	Ethanol	1 mg/mL (2.15 mM)
In vivo	2-hydroxyethyl cellulose, polysorbate 80 with pH adjusted to 2.8 with 1 M HCl	28 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	21.53 mL	107.63 mL	215.26 mL
0.5 mM	4.31 mL	21.53 mL	43.05 mL
1 mM	2.15 mL	10.76 mL	21.53 mL
5 mM	0.43 mL	2.15 mL	4.31 mL

*The above data is based on the productmolecular weight 464.56. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.